SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform
REDMOND, Wash., Sept. 24, 2025 /PRNewswire/ — SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced the presentation…